BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37304009)

  • 1. Transarterial chemoembolization
    Yang B; Yuan M; Yang T; Liao Z; Wu H
    Oncol Res; 2022; 30(1):23-33. PubMed ID: 37304009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis.
    Risaliti M; Bartolini I; Campani C; Arena U; Xodo C; Adotti V; Rosi M; Taddei A; Muiesan P; Amedei A; Batignani G; Marra F
    World J Gastroenterol; 2022 Aug; 28(29):3981-3993. PubMed ID: 36157535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma.
    Chen S; Jin H; Dai Z; Wei M; Xiao H; Su T; Li B; Liu X; Wang Y; Li J; Shen S; Zhou Q; Peng B; Peng Z; Peng S
    Cancer Med; 2019 Apr; 8(4):1530-1539. PubMed ID: 30864247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Li C
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101535. PubMed ID: 33121882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.
    Liu X; Li H; Wang F; Su K; He B; He J; Zhong J; Han Y; Li Z
    BMC Gastroenterol; 2023 Sep; 23(1):299. PubMed ID: 37670232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis.
    Zhu SL; Ke Y; Peng YC; Ma L; Li H; Li LQ; Zhong JH
    PLoS One; 2014; 9(12):e115834. PubMed ID: 25541684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
    Yang B; Zheng B; Yang M; Zeng Z; Yang F; Pu J; Li C; Liao Z
    Hepatol Int; 2018 Sep; 12(5):417-428. PubMed ID: 30073454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
    Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
    Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive intrahepatic therapies for synchronous hepatocellular carcinoma with pulmonary metastasis.
    Hu Z; Huang P; Zhou Z; Li W; Xu J; Xu K; Wang J; Zhang H
    Clin Transl Oncol; 2018 Jun; 20(6):729-739. PubMed ID: 29110217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
    Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
    J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Chen J; Zhou C; Long Y; Yin X
    Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study.
    Li M; Xin Y; Fu S; Liu Z; Li Y; Hu B; Chen S; Liang C; Lu L
    Medicine (Baltimore); 2016 Jan; 95(2):e2458. PubMed ID: 26765441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative transarterial chemoembolization (TACE) + liver resection versus upfront liver resection for large hepatocellular carcinoma (≥5 cm): a systematic review and meta-analysis.
    Chan KS; Tay WX; Cheo FY; Shelat VG
    Acta Chir Belg; 2023 Dec; 123(6):601-617. PubMed ID: 37681991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.